UK markets closed
  • FTSE 100

    6,963.64
    -63.84 (-0.91%)
     
  • FTSE 250

    23,658.94
    +26.10 (+0.11%)
     
  • AIM

    1,275.74
    +3.60 (+0.28%)
     
  • GBP/EUR

    1.1711
    -0.0007 (-0.06%)
     
  • GBP/USD

    1.3737
    -0.0059 (-0.43%)
     
  • BTC-GBP

    34,497.00
    -857.29 (-2.42%)
     
  • CMC Crypto 200

    1,193.48
    -32.05 (-2.62%)
     
  • S&P 500

    4,432.99
    -40.76 (-0.91%)
     
  • DOW

    34,584.88
    -166.44 (-0.48%)
     
  • CRUDE OIL

    71.96
    -0.65 (-0.90%)
     
  • GOLD FUTURES

    1,753.90
    -2.80 (-0.16%)
     
  • NIKKEI 225

    30,500.05
    +176.71 (+0.58%)
     
  • HANG SENG

    24,920.76
    +252.91 (+1.03%)
     
  • DAX

    15,490.17
    -161.58 (-1.03%)
     
  • CAC 40

    6,570.19
    -52.40 (-0.79%)
     

Global Intravenous (IV) Iron Drugs Market Report 2021-2027: Market to Reach $2.6 Billion - Ferric Carboxyl Maltose to Account for $1.2 Billion

·4-min read

Dublin, Sept. 13, 2021 (GLOBE NEWSWIRE) -- The "Intravenous (IV) Iron Drugs - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Global Intravenous (IV) Iron Drugs Market to Reach $2.6 Billion by 2027

Amid the COVID-19 crisis, the global market for Intravenous (IV) Iron Drugs estimated at US$1.7 Billion in the year 2020, is projected to reach a revised size of US$2.6 Billion by 2027, growing at a CAGR of 6.1% over the analysis period 2020-2027.

Ferric Carboxyl Maltose, one of the segments analyzed in the report, is projected to record a 7.4% CAGR and reach US$1.2 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Iron Sucrose segment is readjusted to a revised 5.4% CAGR for the next 7-year period.

The U.S. Market is Estimated at $458.8 Million, While China is Forecast to Grow at 9.4% CAGR

The Intravenous (IV) Iron Drugs market in the U.S. is estimated at US$458.8 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$554.7 Million by the year 2027 trailing a CAGR of 9.5% over the analysis period 2020 to 2027.

Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.2% and 5.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.8% CAGR.

Other Product Types Segment to Record 4.4% CAGR

In the global Other Product Types segment, USA, Canada, Japan, China and Europe will drive the 4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$338.9 Million in the year 2020 will reach a projected size of US$445.5 Million by the close of the analysis period.

China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$344.5 Million by the year 2027, while Latin America will expand at a 5.4% CAGR through the analysis period.

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

  • Iron Deficiency Anemia (IDA) - An Overview

  • Recent Market Activity

  • Intravenous (IV) Iron Drugs Market - A Quick Primer

  • US and Europe Dominate IV Iron Market

  • Asia-Pacific - The Fastest Growing Market

  • Leading Intravenous Iron Drugs Globally

  • Leading IV Iron Drugs Available in the Market

  • Leading Intravenous Iron Drugs: In a Nutshell

  • Ferinject/Injectafer - The Leading Intravenous Iron Drug Globally

  • Venofer - Looses Ground to Ferinject

  • Feraheme Obtains Broader Label Approval

  • Feraheme Obtains FDA Filing Acceptance for Treating All Adult Patients Suffering from IDA

  • Gluconate (Ferrlecit and Nulecit)

  • Dextran

  • Global Market Leaders

2. FOCUS ON SELECT PLAYERS (Total 21 Featured)

  • Allergan Plc. (Ireland)

  • AMAG Pharmaceuticals, Inc. (USA)

  • Daiichi Sankyo, Inc. (USA)

  • Luitpold Pharmaceuticals, Inc. (USA)

  • American Regent, Inc. (USA)

  • Pharmacosmos A/S (Denmark)

  • Sanofi US (USA)

  • Vifor Pharma Ltd. (Switzerland)

  • Vifor Fresenius Medical Care Renal Pharma (Switzerland)

3. MARKET TRENDS & DRIVERS

  • Expanding Pool of ESRD and CKD Patients - The Major Growth Driver for Intravenous (IV) Iron Drugs

  • ESRD Prevalence Statistics: An Opportunity Indicator

  • Increase in Healthcare Spending Bodes Well for Intravenous Iron Drugs Market

  • Dialysis Patients - A Major Market for Intravenous Iron Supplements

  • Ageing Population Drives Demand for IV Iron Drugs

  • Shifting Preference from Oral Iron Drugs to Intravenous Iron Drugs

  • Comparison of Ferrous Salts with IV Iron Therapy

  • Other Chronic Diseases with IDA Offer Prospects for IV Iron Drugs

  • Anemia in Heart Failure - A Market with Huge Potential

  • Chemotherapy Induced Anemia to Promote IV Iron Supplements

  • Correction of IDA in Pregnancy Signals Opportunities

  • Women's Health - A Key Growth Opportunity

  • Perioperative and Postoperative Anemia - A Niche Market Beckons

  • Adverse Reactions of IV Iron Preparations Raise Concerns

  • Dosing Limitations Plague IV Iron Market

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

IV. COMPETITION

For more information about this report visit https://www.researchandmarkets.com/r/mpejrj

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting